Company Disclosure
Financial Performance Highlights (H1FY27 Standalone Un-Audited)
- Revenues from Operations: ₹47.28 crore, representing 458.21% year-on-year growth
- Total Revenues: ₹47.63 crore, representing 409.96% year-on-year growth
- EBITDA: ₹4.12 crore, representing 200.73% year-on-year growth
- Net Profit (PAT): ₹2.44 crore, representing 397.96% year-on-year growth
Orders Announced in FY27 (Cumulative)
1. Sample Order worth ₹10.07 lakhs from an Indo-Canadian joint venture company for supply of oral care products. An MoU has been signed for long-term business. The client is described as one of the world's largest suppliers of luxury amenities, serving 15,000+ hotels and 20+ airlines across 70+ countries and 45+ brands.
2. Orders from New York-based Company for supply of body care products totaling ₹293 lakhs.
3. Orders from Indian FMCG Company for skincare products totaling ₹2,715 lakhs.
4. Order from Indian Pharmacy Retail Network from a leading healthcare company totaling ₹111 lakhs.
5. Sample Order worth ₹15.74 lakhs for supply of Gripe Water from an established buyer based in Sudan.
Key Business Developments
- US FDA Clearance: Veerhealth Care has received US FDA clearance enabling exports of OTC drug products to the USA, which also facilitates access to other international markets.
- Manufacturing Capability: The company describes itself as one of the leading small-cap companies in India in the Food & Drug (OTC) segment with a USFDA-approved plant.
- Russian Market Entry: Discussions with a major Russian group for oral care exports have reached advanced stages, with market entry expected soon.
- E-commerce Expansion: Completed onboarding of Ayuveer products on Myntra, now present across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.
- Production Capacity: Commenced production at new facility with in-house plastic molding for packaging and backward integration.
Financial Guidance
FY 2026-27 Expectations:
- Total Income: ₹105 crores
- PAT: Minimum ₹5-7 crores
- Additional turnover: ₹3-4 crores from Indo-Canadian JV client
FY 2027-28 Expectations:
- Total Income: ₹156 crores
- PAT: Minimum ₹9-11 crores
- Additional turnover: ₹10 crores from Indo-Canadian JV client
Management Commentary
Mr. Bhavin Shah, Managing Director, commented: "I am delighted with the progress we have made in H1FY27 by reporting Highest ever Half Yearly Revenues from Operations of ₹47.28 Crore, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. Due to ongoing GeoPolitical Tensions we could not deliver few of our Export Orders in Q2FY27 which we have started dispatching after easing of these tensions. Going ahead we expect to maintain the high growth rates which we have delivered till now in this Financial Year."
Strategic Focus
The company is actively working towards scaling manufacturing and export operations for products under the medical device category in the U.S. market, in line with its "Local to Global" vision.
Disclaimer
The document contains forward-looking statements subject to risks and uncertainties including government actions, political or economic developments, technological risks, and other factors that could cause actual results to differ materially. The company undertakes no obligation to update these statements.